Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Evidence-Based Evaluation of Classic Herb Pair (Chuanxiong Rhizoma and Salviae Miltiorrhizae) for Preventing Recurrence of Diabetic Lower Extremity Arterial Disease

Taking the approach of promoting qi circulation and activating blood as the entry point, this study targets lower extremity arterial disease(LEAD) patients with TCM syndrome pattern of blood stasis due to qi stagnation. Using Guanxinning Tablets (a herbal formula with qi-moving and blood-activating properties) as the investigational medication, we will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of the classic herb pair (Chuanxiong Rhizoma-Salviae Miltiorrhizae) in preventing LEAD ulcer recurrence. This research aims to accumulate evidence-based medical data supporting new drug development.

Participants needed: 350
Trial details
Phase: Early Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Zheng LiuUpdated: Aug 24, 2025
Eligibility criteria

Age: 18 to 80 years old (inclusive) [+6]

Pure pressure ulcers [+6]

Status: Recruiting

Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis

The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.

Participants needed: 15
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Zheng LiuUpdated: May 7, 2025Locations: 2
Eligibility criteria

1. Patients with allergic rhinitis (in line with the diagnostic criteria of the... [+4]

1. Who are allergic to Arbidol. [+11]